23andMe to Announce Q4 and Full Year FY2024 Financial Performance

23andMe Holding Co. (Nasdaq: ME) has announced that it will be reporting its financial results for the fourth quarter and full fiscal year 2024 on Thursday, May 23, 2024. The company, known for its work in human genetics and biopharmaceuticals, aims to help people access, understand, and benefit from the human genome.

The webcast of the conference call discussing the financial results and business progress will take place at 4:30 p.m. Eastern Time on the same day and can be accessed at https://investors.23andme.com/news-events/events-presentations. A replay of the webcast will also be available at the same address following the event.

In addition, 23andMe will be using the Say Technologies platform to allow both retail and institutional shareholders to submit and upvote questions to management ahead of the earnings conference call. Shareholders can start submitting their questions now at https://app.saytechnologies.com/23andme-2024-q4, and the Q&A platform will remain open until 24 business hours before the earnings call.

23andMe is a genetics-led consumer healthcare and therapeutics company that is focused on creating a healthier future. For more information about the company, interested individuals can visit investors.23andme.com.

While the company is optimistic about its future performance in consumer genetics and therapeutics, it also acknowledges the risks and uncertainties that come with such endeavors. 23andMe urges investors not to place undue reliance on its forward-looking statements and emphasizes that actual results may differ from the projections. The company will continue to update stakeholders on any developments as necessary.